Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

AbbVie's CEO hinted his company may be less willing to invest in psychiatry after a costly setback, while Lilly explained ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 465.16% and ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...